Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Share:

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2022, Vol. 27 ›› Issue (3): 307-313.doi: 10.12092/j.issn.1009-2501.2022.03.010

Previous Articles     Next Articles

Research progress on the relationship between thyroid hormone and idiopathic pulmonary fibrosis

WEI Jifang1, YUE Hongmei1,2, LIU Nanyu1, SONG Peipei1, XIE Yingying1, WANG Jiaqi1, WEI Yaqian1   

  1. 1The First Clinical Medical College of Lanzhou University, Lanzhou 730000, GanSu, China; 2Department of Respiratory Medicine,the First Hospital of Lanzhou University, Lanzhou 730000, GanSu, China
  • Received:2021-12-13 Revised:2022-02-28 Online:2022-03-26 Published:2022-04-11

Abstract: Idiopathic pulmonary fibrosis (IPF) is a chronic progressive disease with unknown etiology, which is characterized by scarring of lung parenchyma, leading to reduced quality of life and premature death. At present, some studies have confirmed that hypothyroidism (HT) may play a role in the development of fibrosis. Many animal experiments have proved that thyroid hormone (TH) can inhibit pulmonary fibrosis by regulating glucose metabolism, improving mitochondrial function and inhibiting inflammation. This paper summarizes the correlation between TH and IPF, and deeply understands the relationship between TH and IPF, in order to have new treatment strategies for IPF in the future.

Key words: thyroid hormone, idiopathic pulmonary fibrosis, glucose metabolism, mitochondrion, inflammation

CLC Number: